Xymphora has written a beautifully researched article on the decision by Health Canada to require the withdrawal of Adderall XR, which is offered as a treatment for attention deficit disorder (ADD), from the Canadian market.

From the NY Times, as quoted by Xymphora—

A day after Canadian officials suspended the use of a hyperactivity drug amid reports of deaths associated with its use, Senator Charles E. Grassley of Iowa contended that United States health officials had asked the Canadian regulators not to do so.

Senator Grassley, a Republican, said on Thursday that the Food and Drug Administration had made the request of Canadian health officials because the F.D.A. could not handle another "drug safety crisis." Mr. Grassley said he was basing his contentions on reports from whistle-blowers within the agency.

Don't miss this one!

Related post
A ceiling as well as a floor (7/25/04)